Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 364.70K | 376.70K | 292.80K | 143.40K | 171.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 364.70K | 376.70K | 292.80K | 143.40K | 171.30K |
| Cost of Revenue | 168.20K | 137.20K | 104.40K | 65.40K | 76.50K |
| Gross Profit | 196.50K | 239.50K | 188.40K | 78.00K | 94.80K |
| SG&A Expenses | 868.50K | 810.00K | 806.30K | 577.30K | 491.60K |
| Depreciation & Amortization | 35.00K | 36.70K | 60.70K | 154.30K | 111.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.10M | 1.00M | 993.10K | 1.02M | 753.60K |
| Operating Income | -739.10K | -626.20K | -700.30K | -879.40K | -582.30K |
| Income Before Tax | -991.90K | -803.00K | -922.30K | -1.53M | -718.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -991.90K | -803.00K | -922.30K | -1.53M | -718.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -991.90K | -803.00K | -922.30K | -1.53M | -718.60K |
| EBIT | -739.10K | -626.20K | -700.30K | -879.40K | -582.30K |
| EBITDA | -704.10K | -589.50K | -656.90K | -798.50K | -470.40K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 124.17M | 123.12M | 121.76M | 108.19M | 103.36M |
| Average Diluted Shares Outstanding | 124.17M | 123.12M | 121.76M | 108.19M | 103.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
